Next-Gen Polymer Therapeutics
Our proprietary POZ Platform™ is based on a synthetic, water soluble, low viscosity polymer called poly (2-oxazoline). During the synthesis steps, a predictable amount of drug is incorporated on the backbone of the polymer using pendant alkyne groups and metal catalyzed “click chemistry”.
The POZ Platform ™ technology provides greater control in drug loading, and the rate of release of attached drugs can often be more precisely controlled. Drugs with narrow therapeutic windows can be designed to maintain more desirable and stable levels in the blood.
The technology is optimized for small molecules and can also be applied to other classes of molecules including proteins and peptides. The application of the platform has been further expanded to optimize the performance of antibody drug conjugates and lipid nanoparticles.
POZ Platform™ Key Advantages
POZ Platform™ is engineered to address the limitations of PEG (polyethylene glycol) and other biocompatible polymers – such as immunogenicity, where unlike PEG, POZ does not elicit an immune response or stimulate development of antibodies to the polymer itself.
-
Drug is attached to multiple pendant groups
-
Single plasma enzyme releases the active drug
-
Can tune release profile of drug and drug load
-
Extends delivery and administration interval
-
Eliminates peak / trough profile for improved safety /efficacy
Enabling Continuous Drug Delivery and Why It Matters
Many drugs, for example those used to treat neurological disorders like Parkinson’s, have narrow therapeutic ranges in which they can work safely and efficaciously. They are often dosed more frequently – resulting in large and frequent fluctuations in drug exposure. They have to be monitored and dose adjusted with greater frequency, and on an individual basis. These fluctuations present clinical, compliance and quality of life challenges for many patients.
